GlassScriptPhysician profile
Mari Bramuchi
NPI 1750911673
$2,579.13
in general payments reported to CMS, 2019-2025
26 companies · $19.00 in 2025
The $19.00 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,799 · 2022: $443 · 2023: $285 · 2024: $33.67 · 2025: $19.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $337.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $555.33 | 2021 | |
| Bard Peripheral Vascular, INC. | $328.83 | 2022-2023 | Pristine |
| Abbvie INC. | $245.18 | 2021 | |
| Novartis Pharmaceuticals Corporation | $224.75 | 2021-2024 | |
| Medtronic, INC. | $185.08 | 2022-2023 | Chameleon |
| Livanova USA, INC. | $165.55 | 2021 | |
| Tanabe Pharma America, INC. | $112.22 | 2021 | |
| Cordis US Corp. | $80.62 | 2022-2023 | Saber, Mynx Control |
| Astrazeneca Pharmaceuticals LP | $75.93 | 2021 | |
| Sunovion Pharmaceuticals INC. | $64.00 | 2021 | |
| Acadia Pharmaceuticals INC | $62.87 | 2021 | |
| Philips North America LLC | $58.38 | 2023 | |
| Lilly USA, LLC | $57.30 | 2021 | |
| Abbott Laboratories | $56.40 | 2023 | Diamondback Peripheral |
| Teva Pharmaceuticals USA, INC. | $54.77 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $44.49 | 2021 | |
| Ucb, INC. | $33.84 | 2021 | |
| Amgen INC. | $29.63 | 2021 | |
| Genzyme Corporation | $21.88 | 2021 | |
| Adlon Therapeutics L.P. | $20.53 | 2021 | |
| Sk Life Science, INC. | $19.98 | 2021 | |
| Novo Nordisk INC | $19.00 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $18.69 | 2021 | |
| Upsher-Smith Laboratories LLC | $16.23 | 2021 | |
| Pfizer INC. | $15.71 | 2021 | |
| Neurelis, INC. | $11.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mari Bramuchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.